他汀类药物使用与年龄相关性黄斑变性进展之间关联的争议：一篇综述。
The controversy over the association between statins use and progression of age-related macular degeneration: a mini review.
作者信息
Peponis Vasileios, Chalkiadakis Spyridon E, Bonovas Stefanos, Sitaras Nikolaos M
机构信息
Athens Eye Hospital, 2nd Eye Clinic, Athens, Greece.
出版信息
Clin Ophthalmol. 2010 Aug 9;4:865-9. doi: 10.2147/opth.s12869.
OBJECTIVE
Age-related macular degeneration (AMD) is the leading cause of blindness in western societies. Statins comprise a class of pharmacological agents that reduce plasma cholesterol levels, and have been shown to prevent progression of atherosclerosis and reduce cardiovascular mortality. The relationship between these medications and AMD has been evaluated in several recent studies. Herein, we examine the current evidence for an association between statin use and risk of AMD.
METHODS
Literature database search (Medline, Scopus, and Science Citation Index Expanded) for articles published up to March 2010, using particular search terms.
RESULTS
From the current evidence available, it is not safe to conclude upon the assumption of a protective effect of statins against age-related maculopathy and AMD.
CONCLUSION
There is a need for large scale prospective studies with a long follow-up period and accurate assessment of AMD to further explore this matter.
目的
年龄相关性黄斑变性（AMD）是西方社会失明的主要原因。他汀类药物是一类可降低血浆胆固醇水平的药物，已被证明可预防动脉粥样硬化进展并降低心血管死亡率。近期多项研究对这些药物与AMD之间的关系进行了评估。在此，我们审视目前关于他汀类药物使用与AMD风险之间关联的证据。
方法
使用特定检索词，对截至2010年3月发表的文章进行文献数据库检索（Medline、Scopus和科学引文索引扩展版）。
结果
根据现有证据，假设他汀类药物对年龄相关性黄斑病变和AMD具有保护作用并得出结论是不安全的。
结论
需要开展大规模、长期随访且对AMD进行准确评估的前瞻性研究，以进一步探究此事。
Zotero 插件